Human Caucasian lung large cell carcinoma,drug-resistant revertant
Cell Line Description
The revertant lung cancer cell line COR-L23/R23- was generated by growing the doxorubicin-selected, resistant variant COR-L23/R (Sigma Catalogue number. 96042339) without drug exposure for 24-28 weeks. The cell line, also known as COR-L23/Rev, overexpresses multidrug resistance -associated protein (MRP), but to a lesser extent than the parent line. It was shown that the cell line has the ability to recover quickly, similar levels of MRP expression and resistance as COR-L23/R after a transient exposure to the MDR-drugs doxorubicin and vincristine.
Split sub-confluent cultures (70-80%) 1:3 to 1:6 using 0.25% trypsin or trypsin/EDTA; 5% CO2; 37°C
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.